Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric perennial allergic rhinitis dose-ranging study of intranasal loteprednol etabonate
2005-000006-32Phase 2Completed
- Sponsor
- IVAX
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of loteprednol etabonate in perennial rhinitis (5 arms), sponsored by IVAX. Primary endpoint: Mean change from baseline in average reflective Total Nasal Symptom Score over 28 days. Started Feb 2005; status: completed.
02
Drugs
loteprednol etabonate
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on 2005-000006-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000006-32.